SARS-CoV-2 - Favipiravir - Therapeutic Candidates

SARS-CoV-2 - Favipiravir - Therapeutic Candidates


Favipiravir, also known as T-705 or Avigan, is a pyrazine-derived antiviral used against RNA viruses. This molecule is an inhibitor of the viral RNA-dependent RNA polymerase. Favipiravir is believed to act selectively on RNA polymerases of viruses and not on those of host cells and it has no action on DNA viruses.  Favipiravir would therefore have very few side effects except in pregnant women because it would have a potential for teratogenicity and embryotoxicity in humans. This is why it is currently only marketed in Japan and banned in Europe.
Favipiravir has shown good results against influenza viruses, especially oseltamivir-resistant viruses. A first study, carried out in China, showed that favipiravir could reduce the healing time of Covid-19 from 11 to 4 days for mildly affected patients. Other studies are underway to determine whether favipiravir may be a good candidate for the treatment of Covid-19 caused by CoV-2 SARS.

Cat#
Description
Size
Price Excl. VAT
HY-14768-S
 0,5-1mg 
HY-14768-1mL
 10mM/1mL 
HY-14768-10mg
 10mg 
HY-14768-100mg
 100mg 
HY-14768-5mg
 5mg 
HY-14768-50mg
 50mg 
S6833-100mg
 100mg 
2778-5
 5mg 
2778-25
 25mg 
F103352-0.5mg
 0.5mg 
F103352-1mg
 1mg 
F103350-100mg
 100mg 
F103352-2.5mg
 2.5mg 
F103350-10mg
 10mg 
F103350-1g
 1g 
F103350-250mg
 250mg 
F103350-25mg
 25mg 
449934-10mg
 10mg 
449934-25mg
 25mg 
449935-1mg
 1mg 
449935-500ug
 500ug 
MBS843229-5mg
 5 mg 
MBS843229-25mg
 25 mg 
NB-42-01345-10mg
 10mg 
NB-42-01345-25mg
 25mg 
NB-42-01345-100mg
 100mg